Polycom Inc. (PLCM) Drops 5.24% on February 02

Equities Staff |

Polycom Inc. (PLCM) was one of the Russell 2000's biggest losers for Tuesday February 02 as the stock slid 5.24% to $9.58, a loss of $-0.53 per share. Starting at an opening price of $9.96 a share, the stock traded between $9.50 and $10.04 over the course of the trading day. Volume was 982,653 shares over 7,872 trades, against an average daily volume of 1.16 million shares and a total float of 132.45 million.

The losses send Polycom Inc. down to a market cap of $1.27 billion. In the last year, Polycom Inc. has traded between $14.22 and $9.52, and its 50-day SMA is currently $12.20 and 200-day SMA is $12.11.

The stock has a P/E Ratio of 19.6.

Polycom Inc provides easy-to-use communication solutions that enable enterprise, government, education & healthcare customers to collaborate over distance, time zones and organizational boundaries. Its solutions include Polycom, RealPresence & Platform.

Polycom Inc. is based out of San Jose, CA and has some 3,525 employees. Its CEO is Peter A. Leav.

For a complete fundamental analysis analysis of Polycom Inc. , check out Equities.com’s Stock Valuation Analysis report for PLCM. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Uber

Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…